These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35514529)

  • 41. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
    Lasalvia P; Hernández F; Castañeda-Cardona C; Cuestas JA; Rosselli D
    Value Health Reg Issues; 2020 Dec; 23():13-18. PubMed ID: 31999987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
    Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
    Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
    Del Santo F; Maratea D; Fadda V; Trippoli S; Messori A
    Eur J Clin Pharmacol; 2012 Apr; 68(4):441-8. PubMed ID: 22057838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
    Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla AA; Karkare SU; McGuiness CB; Korn JR
    PLoS One; 2014; 9(2):e88472. PubMed ID: 24516663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    Chitnis T; Arnold DL; Banwell B; Brück W; Ghezzi A; Giovannoni G; Greenberg B; Krupp L; Rostásy K; Tardieu M; Waubant E; Wolinsky JS; Bar-Or A; Stites T; Chen Y; Putzki N; Merschhemke M; Gärtner J;
    N Engl J Med; 2018 Sep; 379(11):1017-1027. PubMed ID: 30207920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
    Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
    Tsivgoulis G; Katsanos AH; Mavridis D; Grigoriadis N; Dardiotis E; Heliopoulos I; Papathanasopoulos P; Karapanayiotides T; Kilidireas C; Hadjigeorgiou GM; Voumvourakis K;
    PLoS One; 2016; 11(9):e0163296. PubMed ID: 27684943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
    Boziki M; Bakirtzis C; Giantzi V; Sintila SA; Kallivoulos S; Afrantou T; Nikolaidis I; Ioannidis P; Karapanayiotides T; Koutroulou I; Parissis D; Grigoriadis N
    Front Neurol; 2021; 12():699844. PubMed ID: 34497577
    [No Abstract]   [Full Text] [Related]  

  • 53. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
    Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
    Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod.
    Diem L; Nedeltchev K; Kahles T; Achtnichts L; Findling O
    Ther Adv Neurol Disord; 2018; 11():1756286418791103. PubMed ID: 30116299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.
    Gärtner J; Chitnis T; Ghezzi A; Pohl D; Brück W; Häring DA; Karlsson G; Putzki N
    Mult Scler J Exp Transl Clin; 2018; 4(2):2055217318778610. PubMed ID: 29854416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis.
    Giovannoni G; Lang S; Wolff R; Duffy S; Hyde R; Kinter E; Wakeford C; Sormani MP; Kleijnen J
    Neurol Ther; 2020 Dec; 9(2):359-374. PubMed ID: 32989721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P; Lasek-Bal A
    Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
    Lees S; Dicker M; Ku JE; Chaganti V; Mew-Sum M; Wang N; Smith A; Oldmeadow C; Goon WL; Bevan M; Lang D; Hinwood M
    BMJ Open; 2021 Nov; 11(11):e051509. PubMed ID: 34728450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    Julian GS; Rosim RP; Carneseca EC; Rigolon J
    PLoS One; 2020; 15(3):e0229768. PubMed ID: 32119696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.